Arrhythmia Management

Introduction to Antiarrhythmic Therapy

• The European Society of Cardiology recommends flecainide as a treatment option for patients with premature ventricular contractions (PVCs) without structural heart disease, at doses between 200-300 mg/day 1

Patient Selection and Evaluation

• Before initiating flecainide therapy, it is essential to rule out structural heart disease by performing echocardiography to assess cardiac structure and function, and considering cardiac MRI if there's suspicion of cardiomyopathy, as recommended by the European Heart Journal 1

Contraindications and Safety Limitations

• Flecainide is contraindicated in patients with structural heart disease, particularly ischemic heart disease, due to increased mortality risk, as supported by 1
• Flecainide is also contraindicated in patients with suspected ischemic heart disease due to increased risk of proarrhythmia and mortality, as stated by the American College of Cardiology, American Heart Association, and Heart Rhythm Society 2

Alternative Therapies

• For patients with structural heart disease, alternative therapies such as beta-blockers (Class I recommendation), non-dihydropyridine calcium channel blockers (Class I recommendation), sotalol or dofetilide (Class IIb recommendation), and amiodarone may be considered, as recommended by the American College of Cardiology 2, 3
• Catheter ablation is a recommended definitive treatment option with high success rates (>95%) for patients with supraventricular tachycardia requiring discontinuation of flecainide due to suspected ischemic heart disease, as suggested by the American College of Cardiology and the Heart Rhythm Society 2, 3

Special Considerations

• In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), flecainide should be considered as an addition to beta-blockers when control of arrhythmias is incomplete, as recommended by the European Heart Journal 1
• Propafenone should be used cautiously or avoided in patients with reduced ejection fraction, conduction system disease, or renal impairment, due to the higher risk of proarrhythmic effects, as suggested by the European Heart Journal 4, 5
• Propafenone can cause ventricular tachycardia, particularly in patients with structural heart disease (high strength of evidence), enhance AV nodal conduction, and worsen heart failure in susceptible patients (moderate level of evidence), as warned by the American College of Cardiology 6
• The American College of Cardiology recommends monitoring QRS duration, exercise testing to detect use-dependent conduction slowing, and periodic electrolyte levels and renal function checks when using propafenone 6
• Patients with suspected ischemic heart disease should be closely monitored during transition to alternative therapy, with consideration of inpatient monitoring if high-risk features are present, and ensuring adequate loading of new antiarrhythmic before discontinuing flecainide 2
• Propafenone is contraindicated in patients with structural heart disease, particularly ischemic heart disease, and in patients with Wolff-Parkinson-White syndrome and pre-excited atrial fibrillation, as stated by the American College of Cardiology 7, 8
• The American Heart Association recommends that propafenone be avoided in patients with obstructive lung disease 9